Provisions for post-trial care
malnutrition
ADVERSE EFFECTS, MALNUTRITION
We do not expect any adverse effects since the ONS (Entrasol Platinum) used in this study is a locally and internationally marketed product, with no adverse effects reported in post-market surveys. After the intervention period, participants will be screened for malnutrition. If the intervention group derives a benefit by improving nutritional status, the control group will be provided with the ONS after the 12 weeks of the study for 3 months. If the malnutrition status of participants does not improve or worsens, participants will be referred for specialist consultation and management.